Modulation of Visually Evoked Potentials by an Antidepressant

This study has been completed.

Sponsored by:	University Hospital Freiburg
Information provided by:	University Hospital Freiburg
ClinicalTrials.gov Identifier:	NCT00263133

Purpose

12 normal healthy controls will be treated with 50 mg sertraline once daily for three weeks. Early amplitudes of visually evoked potentials will be examined at day 0, 10 and 21 and statistically compared. This study aims to examine a putative modulation of synaptic transmission and plasticity by an antidepressant and is part of a series of studies in healthy individuals and depressed patients.

Condition	Intervention
Depression	Drug: Sertraline

MedlinePlus related topics: Antidepressants Depression

Drug Information available for: Sertraline hydrochloride Sertraline

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	Modulation of Visually Evoked Potentials by an Antidepressant

Further study details as provided by University Hospital Freiburg:

Primary Outcome Measures:

Amplitudes and latencies of early visually evoked potentials.

Estimated Enrollment:	12
Study Start Date:	December 2005
Estimated Study Completion Date:	January 2006

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

healthy individuals 18-65 years

Exclusion Criteria:

history of affective oder other psyhiatric disorder
severe medical condition
pregnancy or ineffective contraception
active illicit drug use

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00263133

Locations

Germany
Dept. of Psychiatry, University of Freiburg
Freiburg, Germany, 79104

Sponsors and Collaborators

University Hospital Freiburg

Investigators

Principal Investigator:

Claus Normann, MD

Dept. of Psychiatry, University of Freiburg

More Information

Study ID Numbers:	VEP-1, EudraCT 2005-005417-37
Study First Received:	December 6, 2005
Last Updated:	June 1, 2007
ClinicalTrials.gov Identifier:	NCT00263133
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University Hospital Freiburg:

Depression
SSRI
Sertraline
synaptic plasticity
visually evoked potentials

Study placed in the following topic categories:

Depression
Mental Disorders
Mood Disorders
Sertraline

Depressive Disorder
Serotonin
Behavioral Symptoms

Additional relevant MeSH terms:

Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Serotonin Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Physiological Effects of Drugs

Psychotropic Drugs
Serotonin Uptake Inhibitors
Central Nervous System Agents
Pharmacologic Actions
Antidepressive Agents

ClinicalTrials.gov processed this record on January 16, 2009